Robert Peterson is recorded as CEO and Board Member at biote Corp. (BTMD) since June 8, 2026 and CFO at biote Corp. (BTMD). The newest filing on record that lists Robert Peterson as CFO at biote Corp. (BTMD) is dated April 2, 2026. biote Corp. reported in an 8-K filed June 2, 2026 that Robert Peterson was appointed Interim Chief Executive Officer, effective June 8, 2026. biote Corp. reported in an 8-K filed June 2, 2026 that Robert Peterson was appointed director of the Board, effective June 8, 2026. biote Corp. reported in an 8-K filed January 11, 2024 that Robert Peterson was appointed Chief Financial Officer, effective January 8, 2024. The proxy statement of biote Corp. reports total compensation of $1,771,879 for Robert Peterson in fiscal 2024, including a base salary of $420,330. Disclosed compensation is on record for 2 fiscal years. Robert Peterson has spoken on 3 earnings calls across 1 company, most recently for biote Corp. on November 5, 2025. biote Corp. is classified in the Medical Care Facilities industry within the Healthcare sector. Other leadership on record at biote Corp. includes Bret Christensen (CEO and Board Member), Marc Beer (Chairman and Board Member), Mary Elizabeth Conlon (General Counsel) and 7 others.
“Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen’s resignation, and as a director of the Board, each effective June 8, 2026 (the “Effective Date”).”
“Concurrently, the Board appointed Robert Peterson, current Chief Financial Officer and Chief Business Officer of BioTE, as Interim Chief Executive Officer of BioTE to fill the vacancy created by Mr. Christensen’s resignation, and as a director of the Board, each effective June 8, 2026 (the “Effective Date”).”
“Unless otherwise noted, all quarterly financial comparisons in my prepared remarks are made against the third quarter of 2024. Third quarter revenue was $48.0 million, a decrease of 6.7%.”
“Unless otherwise noted, all quarterly financial comparisons in my prepared remarks are made against the second quarter of 2024. Second quarter revenue was approximately flat at $48.9 million, reflecting an 8.4% decrease in procedure revenue that was partially offset by more than 30% sales growth in dietary supplements.”
“First quarter revenue increased 4.4% year-over-year to $46.8 million when compared to the same quarter in 2023. Procedure revenue grew 6.6% from the prior year period, a growth rate consistent with our performance in the fourth quarter of 2023.”
